Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Thousands could be spared chemotherapy after landmark breast cancer study

Thousands of breast cancer patients may be safely spared gruelling chemotherapy following a landmark study.

A trial of more than 10,000 women with the most common form of early breast cancer found the treatment was unnecessary for many after surgery.

The findings will lead to a “fundamental change” in the way the disease is treated, a leading oncologist said, with an estimated 3,000 to 5,000 UK women likely to avoid chemotherapy every year as a result.

Charity Breast Cancer Care said it was a “life-changing breakthrough”.

More than 20,000 women in the UK are diagnosed with hormone-receptor positive, HER2-negative, node-negative breast cancer annually.

Around half of these patients would historically receive chemotherapy after having surgery to remove their tumour, to prevent recurrence of the disease.

However, the results of the TAILORx trial show that only 30% of women with this particular form of early-stage breast cancer benefit from the treatment.

The study, presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, is thought to be the largest breast cancer treatment trial ever conducted.

Dr Alistair Ring, consultant medical oncologist at the Royal Marsden NHS Hospital, in London, said: “I think this is a fundamental change in the way we treat women with early-stage breast cancer and will lead to a considerable number of women no longer needing to have chemotherapy.”

The TAILORx trial used the Oncotype DX test, currently available on the NHS, which allows doctors to predict the likelihood of the breast cancer returning.

A sample of the tumour is tested after surgery for 21 genetic markers, which indicate if it could grow and spread.

Patients with a recurrence score of up to 10 out of 100 have previously been shown not to benefit from chemotherapy, and instead need only hormone treatment.

Those who score 26 or higher on the scale do benefit and currently receive chemotherapy.

However, there was unclear evidence on whether those who fall in between – the vast majority of patients – needed chemotherapy.

The TAILORx study, led by the Montefiore Medical Centre in New York, found women older than 50 with this form of breast cancer and a score of up to 25 did not need chemotherapy.

Under 50s with a score of up to 15 can also be spared the treatment and only receive hormone therapy drugs after surgery, according to the research.

Nine-year survival rates were 93.9% without chemotherapy and 93.8% with chemotherapy, the study found.

Dr Ring said the trial’s reuslts would likely have an immediate impact on UK practice and represented a significant shake-up in the treatment of early-stage breast cancer.

“It is a significant step because it is about avoiding a treatment that, for most people diagnosed with cancer, is what they all fear being suggested to have,” he said.

“I, as an oncologist on Monday in clinic, will offer less chemotherapy that will not be of benefit to patients and that is very reassuring to know that when I am offering patients chemotherapy they are likely to benefit from it.”

Rachel Rawson, clinical nurse specialist at Breast Cancer Care, said: “This life-changing breakthrough is absolutely wonderful news as it could liberate thousands of women from the agony of chemotherapy.

“Every day, women with certain types of breast cancer face the terrible dilemma of whether or not to have the treatment, without hard facts about the benefit for them.

“Side effects, such as hair loss, severe pain and infertility, can be utterly devastating and linger long after they walk out the hospital doors. Yet many endure it to try and avoid the cancer coming back.”

Baroness Delyth Morgan, chief executive of Breast Cancer Now, said the “landmark study” was “fantastic news”.

“This is another significant step towards personalised breast cancer treatment and we hope these practice-changing findings will now help refine our use of chemotherapy on the NHS,” she said.

“Chemotherapy is an absolute cornerstone of breast cancer treatment, but with the side-effects being almost unbearable for some we must ensure it is only given to those that will benefit from it.”

The Oncotype DX genetic test has been available on the NHS since 2013, but the National Institute for Health and Care Excellence (Nice) is currently updating its guidance on whether it should be recommended for use.

Dr Ring said the publication of the trial results was “timely”, adding: “I would be very, very keen that the TAILORx results are incorporated into that evaluation.

“Because this is a huge study. It’s exactly the sort of study that we need to make decisions about these genomic tests.”

Breast Cancer Now also called for Nice to reflect the findings in its guidance.

“With the recent consultation on tumour profiling tests having already closed, it is crucial that Nice has the opportunity to consider these results as soon as possible,” Baroness Morgan said.

Commenting on the findings, Dr Harold Burstein, ASCO expert, said: “This is the most common form of breast cancer in the United States and developed countries and the most challenging decision we make with these patients is whether or not to recommend adjuvant chemotherapy with all its side effects and with its potential benefits.

“For those of you who have ever been a clinician or a patient in a consultation room or a patient in a consultation room, you know there’s a huge difference between saying you might benefit a little bit and saying there’s no benefit for you.”

He added: “This is an extraordinary day for breast cancer doctors and for women who have breast cancer.”

The study of 10,273 women, led by Dr Joseph Sparano, associate director for clinical research at the Montefiore Medical Centre, is published in the New England Journal of Medicine.

Already a subscriber? Sign in

[[title]]

[[text]]